

Supplementary Information – Online Resource 11

Evaluating cost-utility of continuous glucose monitoring in individuals with type 1 diabetes: a systematic review of methods and quality of studies using decision models and/or empirical data.

de Jong LA^{1*} (ORCID ID: 0000-0001-8814-0670), Li X² (ORCID ID: 0000-0002-0225-6937), Emamipour S³, van der Werf S⁴ (ORCID ID: 0000-0001-5856-7657), Postma MJ^{1,5}, van Dijk PR⁶ (ORCID ID: 0000-0002-9702-6551), Feenstra TL² (ORCID ID: 0000-0002-5788-0454)

¹ Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

² Unit of Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands

³ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

⁴ Central Medical Library, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

⁵ Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, Groningen, the Netherlands

⁶ Department of Endocrinology. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

*Corresponding author: t.l.feenstra@rug.nl

Table 1. Cost items included in the studies.

Publication (author year, country)	Treatment costs included?	Complication-related costs included?	Productivity losses included?	Method used for productivity losses	Other indirect or direct non-medical costs included?	Type of other indirect or direct non-medical costs included
Emamipour 2022, The Netherlands [1]	Yes	Yes	Yes	NR	No	
Ly 2014, Australia [2]	Yes	Yes	NA		NA	
Wan 2018, US [3]	Yes	Yes	Yes	NR	Yes	Training in CGM use for clinicians, daily hours devoted to diabetes care
Bilir 2018, Sweden [4]	Yes	Yes	NA		NA	
Chaugule 2017, Canada [5]	Yes	Yes	NA		NA	
Conget 2018, Spain [6]	Yes	Yes	Yes	NR	No	
Gomez 2016, Colombia [7]	Yes	Yes	NA		NA	
Isitt 2022, Australia [8]	Yes	Yes	NA		NA	
Jendle 2017, Sweden [9]	Yes	Yes	Yes	Human capital	No	
Jendle 2019, Sweden [10]	Yes	Yes	Yes	Human capital	No	
Jendle 2021, Sweden [11]	Yes	Yes	Yes	NR	Yes	Training of staff
Kamble 2012, US [12]	Yes	Yes	NA		NA	
Lambadiari 2022, Greece [13]	Yes	Yes	Yes	Human capital	No	
Nicolucci 2018, Italy [14]	Yes	Yes	Yes	Human capital	No	
Riemsma 2016, UK [15]	Yes	Yes	NA		NA	
Roze 2015, Sweden [16]	Yes	Yes	Yes	Human capital	No	
Roze 2016, France [17]	Yes	Yes	NA		NA	
Roze 2016, UK [18]	Yes	Yes	NA		NA	
Roze 2017, Denmark [19]	Yes	Yes	Yes	Human capital	No	

Roze 2019, The Netherlands [20]	Yes	Yes	Yes	Human capital	No	
Roze 2019, Turkey [21]	Yes	Yes	NA		NA	
Roze 2020, UK [22]	Yes	Yes	NA		NA	
Roze 2021, Canada [23]	Yes	Yes	NA		NA	
Roze 2021, UK [24]	Yes	Yes	NA		NA	
Roze 2021, France [25]	Yes	Yes	NA		NA	
Serné 2022, The Netherlands [26]	Yes	Yes	Yes	Human capital	No	
Zhao 2021, China [27]	Yes	Yes	Yes	NR	No	
Garcia-Lorenzo 2018, Spain [28]	Yes	Yes	NA		NA	
Health Quality Ontario 2018, Canada [29]	Yes	Yes	NA		NA	
Huang 2010, US [30]	Yes	Yes	Yes	NR	Yes	Training of staff, time of investigators/coordinators devoted to training/counseling patient, hours per day devoted to diabetes care by patient/primary caregiver/secondary caregiver
McQueen 2011, US [31]	Yes	Yes	Yes	NR	No	
Pease 2020, Australia [32]	Yes	Yes	NA		NA	
Pease 2022, Australia [33]	Yes	Yes	NA		NA	
Rotondi 2022, Canada [34]	Yes	Yes	NA		NA	

Abbreviations: NA, not applicable; NR not reported.

Table 2. CGM- and insulin- related cost items included in the studies.

Publication (author year, country)	Pump	Pump reservoir	Pump infusion set	Pump training	Pump replacement	Sensor	Sensor insertion	Batteries	Transmitter/charger	Glucose meter	Test strips	Lancets	Insulin costs	Outpatient visit
Emamipour 2022, The Netherlands [1]	NA	NA	NA	NA	NA	Yes	No	No	Unclear*	No	No	No	No	No
Ly 2014, Australia [2]	Yes	Yes	Yes	No	Unclear*	Yes	No	Yes	Yes	No	Yes	Yes	Yes	No

Wan 2018, US [3]	NA	NA	NA	NA	NA	Yes	No	No	Yes	No	Yes	No	No	No
Bilir 2018, Sweden [4]	No	No	No	No	No	Yes	No	No	Yes	No	Yes	Yes	Yes	Yes
Chaugule 2017, Canada [5]	NA	NA	NA	NA	NA	Yes	No	No	Yes	No	Yes	No	No	No
Conget 2018, Spain [6]	Yes	No	No	No	No	Yes	Unclear *	Unclear *	Unclear *	No	Unclear *	Unclear *	No	No
Gomez 2016, Colombia [7]	No	No	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Isitt 2022, Australia [8]	NA	NA	NA	NA	NA	Yes	No	No	Yes	No	Yes	No	No	No
Jendle 2017, Sweden [9]	No	No	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Jendle 2019, Sweden [10]	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Jendle 2021, Sweden [11]	Yes	Yes	Yes	Yes	No	Yes	Unclear *	Unclear *	Yes	Unclear *	Yes	Yes	Yes	No
Kamble 2012, US [12]	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Lambadiari 2022, Greece [13]	Yes	No	No	No	Unclear *	Yes	No	No	No	No	Yes	Yes	Yes	No
Nicolucci 2018, Italy [14]	No	No	No	No	No	Yes	No	No	Unclear *	Unclear *	Yes	Unclear *	No	No
Riemsma 2016, UK [15]	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Roze 2015, Sweden [16]	Yes	No	No	No	No	Yes	Yes	Yes	No	No	Yes	Yes	No	No
Roze 2016, France [17]	No	No	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Roze 2016, UK [18]	No	No	No	No	No	Yes	No	No	Yes	No	Yes	Yes	No	No
Roze 2017, Denmark [19]	No	No	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Roze 2019, The Netherlands [20]	No	No	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Roze 2019, Turkey [21]	No	No	No	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
Roze 2020, UK [22]	NA	NA	NA	NA	NA	Yes	No	No	Yes	Unclear *	Yes	Yes	No	No
Roze 2021, Canada [23]	NA	NA	NA	NA	NA	Yes	No	No	Yes	Unclear *	Yes	Yes	No	No
Roze 2021, UK [24]	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Unclear *	Yes	Yes	Yes	Yes
Roze 2021, France [25]	NA	NA	NA	NA	NA	Yes	No	No	Yes	Unclear *	Unclear *	Unclear *	No	No
Serné 2022, The Netherlands [26]	Yes	No	No	No	Unclear *	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No

Zhao 2021, China [27]	NA	NA	NA	NA	NA	Yes	No	No	Unclear *	Unclear *	Yes	Yes	Yes	No
Garcia-Lorenzo 2018, Spain [28]	No	No	No	No	No	Yes	No	No	Yes	Yes	Yes	No	No	No
Health Quality Ontario 2018, Canada [29]	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	No	Yes	No	Yes	No
Huang 2010, US [30]	Yes	Unclear *	Unclear *	Yes	Unclear *	Yes	No	No	Yes	No	Yes	Yes	Yes	No
McQueen 2011, US [31]	NA	NA	NA	NA	NA	Yes	No	Yes	Yes	No	No	No	No	No
Pease 2020, Australia [32]	Yes	Yes	Yes	No	Unclear *	Yes	No	Yes	Yes	Unclear *	Yes	Unclear *	No	No
Pease 2022, Australia [33]	No	Yes	Yes	No	Unclear *	Yes	No	Yes	Yes	Unclear *	Yes	Unclear *	No	No
Rotondi 2022, Canada [34]	NA	NA	NA	NA	NA	Yes	No	No	No	No	Yes	No	No	No

* Reported as unclear if implied in text, but not clear from tables in the included study.

Abbreviations: NA, not applicable.




Figure 1. Proportion of studies that included CGM- and insulin-related unit costs.

References

1. Emami-pour S, van Dijk PR, Bilo HJG, Edens MA, van der Galiën O, Postma MJ, et al. Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring (isCGM) Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9). *J Diabetes Sci Technol*. 2022.
2. Ly TT, Brnabic AJM, Eggleston A, Kolivos A, McBride ME, Schrover R, et al. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. *Value Health*. 2014;17:561–9.
3. Wan W, Skandari MR, Minc A, Nathan AG, Winn A, Zarei P, et al. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. *Diabetes Care*. 2018;41:1227–34.

4. Bilir SP, Hellmund R, Wehler B, Li H, Munakata J, Lamotte M. Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden. *Eur Endocrinol.* 2018;14:73–9.
5. Chaugule S, Graham C. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective. *J Med Econ.* 2017;20:1128–35.
6. Conget I, Martín-Vaquero P, Roze S, Elías I, Pineda C, Álvarez M, et al. Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. *Endocrinol Diabetes Nutr.* 2018;65:380–6.
7. Gomez AM, Alfonso-Cristancho R, Orozco JJ, Lynch PM, Prieto D, Saunders R, et al. Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia. *Endocrinol Nutr.* 2016;63:466–74.
8. Isitt JJ, Roze S. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia: Response to letter from Hellmund, Richard and Welsh, Zoe. *Diabet Med.* 2023;40.
9. Jendle J, Smith-Palmer J, Delbaere A, de Portu S, Papo N, Valentine W, et al. Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. *Diabetes Ther.* 2017;8:1015–30.
10. Jendle J, Pöhlmann J, De Portu S, Smith-Palmer J, Roze S. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. *Diabetes Technol Ther.* 2019;21:110–8.
11. Jendle J, Buompiensiere MI, Holm AL, de Portu S, Malkin SJP, Cohen O. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. *Diabetes Ther.* 2021;12:2977–91.
12. Kamble S, Schulman KA, Reed SD. Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. *Value Health.* 2012;15:632–8.
13. Lambadiari V, Ozdemir Saltik AZ, De Portu S, Buompiensiere MI, Kountouri A, Korakas E, et al. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece. *Diabetes Technol Ther.* 2022;24:316–23.
14. Nicolucci A, Rossi MC, D'Ostilio D, Delbaere A, de Portu S, Roze S. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. *Nutr Metab Cardiovasc Dis.* 2018;28:707–15.
15. Riemsma R, Ramos IC, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, et al. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. *Health Technol Assess.* 2016;20:1–252.
16. Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. *Diabet Med.* 2015;32:618–26.
17. Roze S, Smith-Palmer J, Valentine W, Payet V, De Portu S, Papo N, et al. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. *Diabetes Technol Ther.* 2016;18:75–84.
18. Roze S, Smith-Palmer J, Valentine WJ, Cook M, Jethwa M, De Portu S, et al. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. *J Med Econ.* 2016;19:236–42.
19. Roze S, de Portu S, Smith-Palmer J, Delbaere A, Valentine W, Ridderstråle M. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark. *Diabetes Res Clin Pract.* 2017;128:6–14.

20. Roze S, Smith-Palmer J, De Portu S, Delbaere A, De Brouwer B, De Valk HW. Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. *Clinicoecon Outcomes Res.* 2019;11:73–82.
21. Roze S, Smith-Palmer J, De Portu S, Özdemir Saltik AZ, Akgül T, Deyneli O. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. *Diabetes Technol Ther.* 2019;21:727–35.
22. Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. *Diabetes Care.* 2020;43:2411–7.
23. Roze S, Isitt JJ, Smith-Palmer J, Lynch P. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. *Clinicoecon Outcomes Res.* 2021;13:717–25.
24. Roze S, Buompensiere MI, Ozdemir Z, de Portu S, Cohen O. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK. *J Med Econ.* 2021;24:883–90.
25. Roze S, Isitt JJ, Smith-Palmer J, Lynch P, Klinkenbijn B, Zammit G, et al. Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France. *Diabetes Ther.* 2021;12:235–46.
26. Serné EH, Roze S, Buompensiere MI, Valentine WJ, De Portu S, de Valk HW. Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands. *Adv Ther.* 2022;39:1844–56.
27. Zhao X, Ming J, Qu S, Li HJ, Wu J, Ji L, et al. Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in China. *Diabetes Ther.* 2021;12:3079–92.
28. García-Lorenzo B, Rivero-Santana A, Vallejo-Torres L, Castilla-Rodríguez I, García-Pérez S, García-Pérez L, et al. Cost-effectiveness analysis of real-time continuous monitoring glucose compared to self-monitoring of blood glucose for diabetes mellitus in Spain. *J Eval Clin Pract.* 2018;24:772–81.
29. Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment. Ontario; 2018 Feb.
30. Huang ES, O’Grady M, Basu A, Winn A, John P, Lee J, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. *Diabetes Care.* 2010;33:1269–74.
31. McQueen RB, Ellis SL, Campbell JD, Nair K V., Sullivan PW. Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. *Cost Eff Resour Alloc.* 2011;9.
32. Pease A, Zomer E, Liew D, Earnest A, Soldatos G, Ademi Z, et al. Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. *Diabetes Technol Ther.* 2020;22:812–21.
33. Pease A, Callander E, Zomer E, Abraham MB, Davis EA, Jones TW, et al. The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth. *Diabetes Care.* 2022;45:1971–80.
34. Rotondi MA, Wong O, Riddell M, Perkins B. Population-Level Impact and Cost-effectiveness of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring Technologies for Adults With Type 1 Diabetes in Canada: A Modeling Study. *Diabetes Care.* 2022;45:2012–9.